AI Article Synopsis
- mRNA technology is transforming therapies like vaccines and gene editing, thanks to its rapid development.
- Lipid nanoparticles (LNPs) are key for delivering mRNA but mainly target the liver, which restricts their effectiveness for other diseases.
- The review discusses ways to improve organ-specific mRNA delivery using LNPs, focusing on new lipid designs, targeted ligands, and formulation optimizations to enhance treatment effectiveness.
Article Abstract
Messenger RNA (mRNA) technology has rapidly evolved, significantly impacting various therapeutic applications, including vaccines, protein replacement, and gene editing. Lipid nanoparticles (LNPs) have emerged as a pivotal nonviral vector for mRNA delivery, crucial for organ-targeted therapies. Despite their success, most LNP formulations predominantly target the liver, limiting their use in nonliver diseases. This review explores strategies to achieve organ-specific mRNA delivery using LNPs, including the discovery of new lipid structures, modification of targeting ligands, incorporation of additional components, and optimization of LNP formulations. These advancements aim to enhance the precision and efficacy of mRNA therapeutics across a broader range of diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/wnan.2004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!